budesonide foam Uceris
Selected indexed studies
- Hold the Foam: Why Topical Budesonide Remains Relevant for IBD Therapy. (Dig Dis Sci, 2020) [PMID:32189103]
- Topical therapy. (Dig Dis, 2012) [PMID:23295698]
- Budesonide rectal foam (Uceris) for ulcerative colitis. (Med Lett Drugs Ther, 2015) [PMID:26529134]
_Worker-drafted node — pending editorial review._
Connections
budesonide foam Uceris is a side effect of
Sources
- Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial. (2022) pubmed
- Topical therapy. (2012) pubmed
- Budesonide foam for mild to moderate distal ulcerative colitis: A systematic review and meta-analysis. (2017) pubmed
- Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. (2015) pubmed
- Budesonide rectal foam (Uceris) for ulcerative colitis. (2015) pubmed
- [Ulcerative colitis]. (2016) pubmed
- Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. (2006) pubmed
- Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. (2015) pubmed
- Budesonide foam vs. hydrocortisone acetate foam in the treatment of active ulcerative proctosigmoiditis. (2003) pubmed
- Hold the Foam: Why Topical Budesonide Remains Relevant for IBD Therapy. (2020) pubmed